Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

Show other versions (1)

BACKGROUND: Tumour necrosis factor (TNF)-alpha inhibitors are beneficial for the treatment of rheumatoid arthritis (RA) in terms of reducing the risk of joint damage, improving physical function and improving quality of life. This Cochrane review is an update of a review of the treatment of RA with...

תיאור מלא

מידע ביבליוגרפי
Main Authors:	Ruiz Garcia, V, Jobanputra, P, Burls, A, Cabello, J, Vela Casasempere, P, Bort-Marti, S, Kynaston-Pearson, F
פורמט:	Journal article
שפה:	English
יצא לאור:	2014

פריטים דומים

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
מאת: Ruiz Garcia, V, et al.
יצא לאור: (2011)

Certolizumab pegol in therapy for rheumatoid arthritis
מאת: Galina Viktorovna Lukina, et al.
יצא לאור: (2012-06-01)

Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis
מאת: M Connock, et al.
יצא לאור: (2010-10-01)

QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL
מאת: Vera Nikolayevna Amirdjanova, et al.
יצא לאור: (2012-10-01)

New aspects of the pharmacotherapy of rheumatoid arthritis: a focus on certolizumab pegol
מאת: Evgeniy L'vovich Nasonov, et al.
יצא לאור: (2011-02-01)

Multifocal tuberculosis on certolizumab pegol in a patient followed for rheumatoid arthritis
מאת: Emna Hannech, et al.
יצא לאור: (2021-06-01)

New treatment possibilities for rheumatoid arthritis: the Russian experience in using certolizumab pegol
מאת: Dmitry Evgenyevich Karateev, et al.
יצא לאור: (2012-04-01)

EFFICACY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF PSORIATIC ARTHRITIS
מאת: T. V. Korotaeva, et al.
יצא לאור: (2015-10-01)

Certolizumab pegol – new option in the treatment of psoriatic arthritis
מאת: Maria Majdan, et al.
יצא לאור: (2014-07-01)

Certolizumab pegol in the treatment of spondyloarthritis
מאת: Mariusz Korkosz
יצא לאור: (2014-09-01)

Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis
מאת: Smolen, JS, et al.
יצא לאור: (2024)

COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE OR AS MONOTHERAPY FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS IN THE UNITED KINGDOM
מאת: Purcaru, O, et al.
יצא לאור: (2010)

Prefilled certolizumab pegol (Cimzia&reg;) syringes for self-use in the treatment of rheumatoid arthritis
מאת: J Rosa, et al.
יצא לאור: (2010-08-01)

CERTOLIZUMAB PEGOL IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS
מאת: Sh. F. Erdes
יצא לאור: (2016-02-01)

Eosinophilic Annular Erythema Due to Certolizumab Pegol Therapy for Rheumatoid Arthritis Post-COVID-19 Vaccine
מאת: Andrea Bassi, et al.
יצא לאור: (2023-04-01)

The efficacy of certolizumab pegol in rheumatoid arthritis assessed by gray scale and power Doppler ultrasonography: case reports
מאת: José Alexandre Mendonça, et al.
יצא לאור: (2019-02-01)

Exposure–Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis
מאת: Stéphane Paul, et al.
יצא לאור: (2020-07-01)

Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol
מאת: Mehmet Baysal, et al.
יצא לאור: (2018-09-01)

Treatment of pyoderma gangrenosum in pregnancy with certolizumab pegol
מאת: Lindsey J. Wanberg, et al.
יצא לאור: (2024-06-01)

Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials
מאת: Tanaka, Y, et al.
יצא לאור: (2023)

Experience with long-term use of certolizumab pegol (Cimzia)
מאת: Karine Arnoldovna Lytkina, et al.
יצא לאור: (2013-10-01)

Experience with long-term use of certolizumab pegol (Cimzia)
מאת: Karine Arnoldovna Lytkina, et al.
יצא לאור: (2013-10-01)

A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population.
מאת: Ian R White, et al.
יצא לאור: (2022-01-01)

A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population
מאת: Ian R. White, et al.
יצא לאור: (2022-01-01)

Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data
מאת: Vivian P. Bykerk, et al.
יצא לאור: (2023-02-01)

Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study
מאת: Glatt, S, et al.
יצא לאור: (2019)

Quantitation of certolizumab pegol by validated liquid chromatography methods
מאת: Clóvis Dervil Appratto Cardoso Júnior, et al.
יצא לאור: (2023-11-01)

Certolizumab pegol in treatment of Crohn's disease with perianal lesions
מאת: I.L. Khalif, et al.
יצא לאור: (2018-04-01)

Active axial spondyloarthritis: potential role of certolizumab pegol
מאת: Ranatunga S, et al.
יצא לאור: (2014-02-01)

Certolizumab pegol w leczeniu reumatoidalnego zapalenia stawów
מאת: Piotr Wiland, et al.
יצא לאור: (2011-08-01)

An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy
מאת: Acosta-Felquer ML, et al.
יצא לאור: (2016-03-01)

CERTOLIZUMAB PEGOL IN THE TREATMENT OF TAKAYASU ARTERITIS: THE FIRST EXPERIENCE AND PROSPECTS
מאת: P. I. Novikov, et al.
יצא לאור: (2018-07-01)

Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol.
מאת: Hazes, J, et al.
יצא לאור: (2010)

Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis
מאת: A. Spadaro, et al.
יצא לאור: (2013-07-01)

Patient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn's Disease
מאת: Wojciech Blonski, et al.
יצא לאור: (2012-04-01)

Efficacy and tolerability of certolizumab pegol in Crohn's disease in clinical practice
מאת: O V Knyazev, et al.
יצא לאור: (2018-06-01)

Certolizumab pegol – Tumor necrosis factor inhibitor for refractory uveitis
מאת: Yael Sharon, et al.
יצא לאור: (2020-06-01)

Possible relationship between certolizumab pegol and arrhythmias: report of two cases
מאת: R. Talotta, et al.
יצא לאור: (2016-09-01)

Effectiveness of Certolizumab Pegol in Treating Rheumatoid Arthritis Patients with Persistent Inflamed Residual Mono- or Oligosynovitis Resistant to Prior TNF-α Inhibitors
מאת: Syuichi Koarada, et al.
יצא לאור: (2015-01-01)

Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment
מאת: Jeffrey R. Curtis, et al.
יצא לאור: (2017-12-01)